Neon Bloom, Inc. (NBCO)
USD 0.01
(-7.0%)
USD 0.01
(-7.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -389.57 Thousand USD | 2.43% |
| 2022 | -399.27 Thousand USD | 68.95% |
| 2021 | -1.28 Million USD | -1381.39% |
| 2020 | -86.79 Thousand USD | 99.58% |
| 2019 | -20.52 Million USD | -4515.46% |
| 2018 | -444.69 Thousand USD | 17.14% |
| 2017 | -536.68 Thousand USD | -1266132.54% |
| 2016 | -42.38 USD | 0.0% |
| 2010 | -1.5 Million USD | -730.87% |
| 2009 | -181.1 Thousand USD | -27.19% |
| 2008 | -142.38 Thousand USD | 88.05% |
| 2007 | -1.19 Million USD | -2672.02% |
| 2006 | -42.97 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -12.53 Thousand USD | 93.9% |
| 2024 Q2 | 650.69 Thousand USD | 5293.04% |
| 2023 Q2 | 6210.00 USD | 113.5% |
| 2023 Q1 | -45.99 Thousand USD | -308.8% |
| 2023 Q4 | -205.31 Thousand USD | -4.64% |
| 2023 FY | -389.57 Thousand USD | 2.43% |
| 2023 Q3 | -196.2 Thousand USD | -3259.42% |
| 2022 Q1 | -109.09 Thousand USD | 90.59% |
| 2022 FY | -399.27 Thousand USD | 68.95% |
| 2022 Q4 | -11.25 Thousand USD | -118.85% |
| 2022 Q3 | 59.67 Thousand USD | 117.62% |
| 2022 Q2 | -338.59 Thousand USD | -210.38% |
| 2021 Q4 | -1.15 Million USD | -1417.09% |
| 2021 Q3 | -76.38 Thousand USD | -4673.65% |
| 2021 Q2 | 1670.00 USD | 102.13% |
| 2021 Q1 | -78.57 Thousand USD | -3732.68% |
| 2021 FY | -1.28 Million USD | -1381.39% |
| 2020 Q3 | -4.02 USD | 0.0% |
| 2020 FY | -86.79 Thousand USD | 99.58% |
| 2020 Q4 | -2050.00 USD | -50895.02% |
| 2019 FY | -20.52 Million USD | -4515.46% |
| 2018 FY | -444.69 Thousand USD | 17.14% |
| 2017 Q3 | -8.99 USD | 0.0% |
| 2017 FY | -536.68 Thousand USD | -1266132.54% |
| 2017 Q4 | -8.99 USD | 0.0% |
| 2016 FY | -42.38 USD | 0.0% |
| 2016 Q3 | -6.26 USD | 0.0% |
| 2016 Q4 | -6.26 USD | 0.0% |
| 2015 Q4 | -3.53 USD | 0.0% |
| 2015 Q3 | -3.53 USD | 0.0% |
| 2011 Q1 | -201.69 Thousand USD | 78.86% |
| 2010 Q1 | -168.67 Thousand USD | -115.72% |
| 2010 Q2 | -141.75 Thousand USD | 15.96% |
| 2010 Q3 | -245.45 Thousand USD | -73.15% |
| 2010 Q4 | -953.97 Thousand USD | -288.65% |
| 2010 FY | -1.5 Million USD | -730.87% |
| 2009 Q2 | -113.74 Thousand USD | -192.97% |
| 2009 FY | -181.1 Thousand USD | -27.19% |
| 2009 Q4 | -78.19 Thousand USD | -274.17% |
| 2009 Q3 | 44.89 Thousand USD | 139.47% |
| 2009 Q1 | -38.82 Thousand USD | 51.28% |
| 2008 Q4 | -79.69 Thousand USD | -3141.64% |
| 2008 FY | -142.38 Thousand USD | 88.05% |
| 2008 Q3 | 2620.00 USD | 104.14% |
| 2008 Q2 | -63.33 Thousand USD | -3100.51% |
| 2008 Q1 | -1979.00 USD | 99.71% |
| 2007 Q1 | -50.22 Thousand USD | 0.0% |
| 2007 Q2 | -181.71 Thousand USD | -261.84% |
| 2007 Q3 | -272.58 Thousand USD | -50.01% |
| 2007 Q4 | -686.69 Thousand USD | -151.92% |
| 2007 FY | -1.19 Million USD | -2672.02% |
| 2006 FY | -42.97 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 70.828% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 92.277% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 97.817% |
| Nascent Biotech, Inc. | -2.22 Million USD | 82.53% |
| Rebus Holdings, Inc. | -664 Thousand USD | 41.33% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.476% |
| Qrons Inc. | -643.67 Thousand USD | 39.477% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.298% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 6.236% |
| Skye Bioscience, Inc. | -13.67 Million USD | 97.151% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.457% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 107.926% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -48.847% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.486% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 86.333% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 74.638% |
| Mesoblast Limited | -84.14 Million USD | 99.537% |
| Marizyme, Inc. | -34.08 Million USD | 98.857% |
| Genus plc | 6.4 Million USD | 106.087% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 103.999% |
| Pharming Group N.V. | -4.87 Million USD | 92.016% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 80.389% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 58.173% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 95.334% |
| ContraFect Corporation | -56.88 Million USD | 99.315% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 91.447% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 72.213% |
| IMV Inc. | -38.67 Million USD | 98.993% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 85.838% |
| MultiCell Technologies, Inc. | -722.81 USD | -53796.598% |
| ONE Bio Corp. | 13.68 Million USD | 102.847% |
| Accustem Sciences Inc. | -3.74 Million USD | 89.602% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.34% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 19.354% |
| Q BioMed Inc. | -3.44 Million USD | 88.694% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 111.005% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 85.173% |
| Biomind Labs Inc. | -1 Million USD | 61.414% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.291% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 86.572% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 94.14% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 79.104% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -1200.648% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 97.545% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 79.842% |
| GB Sciences, Inc. | -1.42 Million USD | 72.575% |
| Alpha Cognition Inc. | -9.7 Million USD | 95.986% |
| HST Global, Inc. | -140.9 Thousand USD | -176.473% |
| CSL Limited | 3.7 Billion USD | 100.011% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 65.369% |
| Halberd Corporation | -75.05 Thousand USD | -419.081% |
| Enzolytics Inc. | -2.14 Million USD | 81.87% |
| Agentix Corp. | -1.37 Million USD | 71.601% |
| Resverlogix Corp. | -12.74 Million USD | 96.944% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 87.704% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.908% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 62.685% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 86.656% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 75.334% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 88.559% |
| AVAX Technologies, Inc. | 6.69 Million USD | 105.821% |
| Zenith Capital Corp. | -8.94 Million USD | 95.644% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.906% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -2136.209% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 84.134% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -127.142% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 80.568% |
| Kadimastem Ltd | -3.04 Million USD | 87.186% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 60.412% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 68.983% |
| BioStem Technologies, Inc. | -7.77 Million USD | 94.992% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -114.657% |
| LadRx Corporation | -3.82 Million USD | 89.812% |
| Cell Source, Inc. | -4.32 Million USD | 90.993% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 43.29% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 43.29% |
| NovAccess Global Inc. | -2.46 Million USD | 84.207% |
| Affymax, Inc. | -15.04 Million USD | 97.411% |
| Itoco Inc. | -919.14 Thousand USD | 57.616% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 90.809% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 65.186% |
| Mobile Lads Corp. | -554.55 Thousand USD | 29.75% |
| CytoDyn Inc. | -18.05 Million USD | 97.843% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -1447.755% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -77.015% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 31.016% |
| SYBLEU INC | -149.18 Thousand USD | -161.141% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 78.552% |
| International Stem Cell Corporation | -663 Thousand USD | 41.241% |
| Bioxytran, Inc. | -3.82 Million USD | 89.802% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -640.065% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -1815.29% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 98.926% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 75.923% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 47.057% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 87.478% |
| Neutra Corp. | -229.48 Thousand USD | -69.758% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 97.779% |
| PureTech Health plc | -146.19 Million USD | 99.734% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 98.187% |
| IXICO plc | -1.43 Million USD | 72.89% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 95.895% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.68% |
| CSL Limited | 3.81 Billion USD | 100.01% |
| Cellectis S.A. | -108.85 Million USD | 99.642% |